CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 55 enrolled
Drug / intervention
Topiramate add-on therapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01627860
NCT01627860Phase 4Completed

Topiramate in the Treatment of Epilepsy: 1st Add-on vs. Mono-therapy Study in Neuro-Surgical Patients

Johnson & Johnson Taiwan Ltd·interventional·Posted Jun 26, 2012·Updated Oct 29, 2013

In Brief

A Phase 4 clinical trial evaluating Topiramate add-on therapy and Topiramate monotherapy for Epilepsy. Completed, enrolled 55 participants.

Detailed Summary

The purpose of this study is to examine seizure control and tolerability of Topiramate after either transitioning from previous antiepileptic drug (AED) or adding on to previous AED.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 26, 2012
Enrollment StartFeb 1, 2010
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.0 years ago

Interventions

Topiramate add-on therapydrug

Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.

Topiramate monotherapydrug

Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.